Education
About Us
Working with TipRanks
Follow Us
RenovoRx (RNXT)
NASDAQ:RNXT
RNXT Stock Chart & Stats
$1.15
-$0.05(-3.65%)
At close: 4:00 PM EST
$1.15
-$0.05(-3.65%)
Day’s Range― - ―
52-Week Range$0.75 - $1.69
Previous CloseN/A
Volume39.72K
Average Volume (3M)758.30K
Market Cap
$41.41M
Enterprise Value$36.04M
Total Cash (Recent Filing)$12.31M
Total Debt (Recent Filing)$260.00K
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Nov 17, 2025EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding36,645,885
10 Day Avg. Volume570,538
30 Day Avg. Volume758,300
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue54.45
Enterprise Value/Gross Profit86.64
Enterprise Value/Ebitda-3.14
Forecast
1Y Price Target
$6.33Price Target Upside450.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe independent Data Monitoring Committee for its ongoing Phase III TIGeR-PaC trial recently completed their review of the second pre-planned interim analysis and has recommended that the trial continue.
Financial PerformanceRenovoRx reported its fiscal Q2 2025 results with revenue exceeding estimates, indicating strong revenue growth.
Product CommercializationRenovoRx is now actively commercializing its FDA-cleared RenovoCath as a standalone FDA-cleared proprietary medical device.
Bears Say
Data PublicationThe deferral of interim data publication may have contributed to the decline in RNXT share prices.
Market ReactionRNXT shares were down on the news, likely due to deferring publication of interim data.
RenovoRx News
RNXT FAQ
What was RenovoRx’s price range in the past 12 months?
RenovoRx lowest stock price was $0.75 and its highest was $1.69 in the past 12 months.
What is RenovoRx’s market cap?
RenovoRx’s market cap is $41.41M.
When is RenovoRx’s upcoming earnings report date?
RenovoRx’s upcoming earnings report date is Nov 17, 2025 which is in 23 days.
How were RenovoRx’s earnings last quarter?
RenovoRx released its earnings results on Aug 14, 2025. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.085 by $0.005.
Is RenovoRx overvalued?
According to Wall Street analysts RenovoRx’s price is currently Undervalued.
Does RenovoRx pay dividends?
RenovoRx does not currently pay dividends.
What is RenovoRx’s EPS estimate?
RenovoRx’s EPS estimate is -0.08.
How many shares outstanding does RenovoRx have?
RenovoRx has 36,645,885 shares outstanding.
What happened to RenovoRx’s price movement after its last earnings report?
RenovoRx reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.085. Following the earnings report the stock price went down -22.581%.
Which hedge fund is a major shareholder of RenovoRx?
Currently, no hedge funds are holding shares in RNXT
RenovoRx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.33 (450.43% Upside)
$6.33 (450.43% Upside)
Blogger Sentiment
Bullish
RNXT Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $9.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.6%
Last 30 Days ▲ 4.5%
Last 30 Days ▲ 4.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.34%
12-Months-Change
Fundamentals
Return on Equity
-107.11%
Trailing 12-Months
Asset Growth
13.65%
Trailing 12-Months
Company Description
RenovoRx
RenovoRx (RNXT) is a biopharmaceutical company focused on developing targeted therapies for cancer treatment. The company is dedicated to improving patient outcomes by delivering chemotherapy directly to tumors via its proprietary RenovoTAMP (Trans-Arterial Micro-Perfusion) therapy platform. This platform is designed to enhance the efficacy of existing chemotherapeutic agents while minimizing systemic exposure and associated side effects.
RNXT Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with significant achievements in commercial sales and clinical trial progress, despite challenges in sales infrastructure and ongoing R&D expenses.View all RNXT earnings summariesRNXT Stock 12 Month Forecast
Average Price Target
$6.33
▲(450.43% Upside)
Technical Analysis
Ovid Therapeutics
―
Grace Therapeutics
―
Jasper Therapeutics
―
Neurosense Therapeutics Ltd.
―
PepGen Inc.
―
Ownership Overview
3.34% Insiders
5.51% Mutual Funds
0.36% Other Institutional Investors
86.92% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---